Drug designed by AI to enter human trials for first time․ #TheTelegraph
2178
Sunday, 02 February, 2020, 00:30
The first drug designed entirely using artificial intelligence is entering clinical human trials in what has been described as a major milestone in medicine. The new compound, which has been designed for treating obsessive-compulsive disorder, was discovered using Oxford-based biotech company Exscientia's AI system. Japan's Sumitomo Dainippon Pharma partnered with Exscientia to use the platform, which automatically analyses patients' genetic data and finds molecules that could be used in new medication. To get a drug to this stage of development would normally take around four and a half years, but using the AI-tools, it took less than 12 months. |
SpaceX Starship ‘Lost’ After Reaching Space During Third Test Flight
555214.03.2024, 20:27Neuralink's first human patient can control mouse through thinking, says Elon Musk
435320.02.2024, 15:24A Bronze Age lip-paint from southeastern Iran (photo)
337106.02.2024, 20:24Apple thinks iOS 18 might be the ‘biggest’ iOS update ever
201903.02.2024, 20:06Elon Musk's Neuralink implants brain chip in first human (video)
343730.01.2024, 10:30Nokia smartphone brand will soon disappear: Why has it failed to gain a place in the market?
494218.01.2024, 23:48